Cadila Healthcare trades in green on the BSE

29 Mar 2019 Evaluate

Cadila Healthcare is currently trading at Rs. 340.20, up by 4.45 points or 1.33% from its previous closing of Rs. 335.75 on the BSE.

The scrip opened at Rs. 337.95 and has touched a high and low of Rs. 340.40 and Rs. 337.00 respectively. So far 17343 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 432.40 on 10-Sep-2018 and a 52 week low of Rs. 306.35 on 15-Feb-2019.

Last one week high and low of the scrip stood at Rs. 341.95 and Rs. 327.55 respectively. The current market cap of the company is Rs. 34525.72 crore.

The promoters holding in the company stood at 74.79%, while Institutions and Non-Institutions held 17.33% and 7.88% respectively.

Zydus Cadila has received the final approval from the United States Food & Drug Administration (USFDA) to market Ambrisentan Tablets USP (US RLD-Letairis Tablets), 5 mg and 10 mg. It is used to treat high blood pressure in the lungs (pulmonary arterial hypertension) and will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad. The US sales of Ambrisentan Tablets USP stood at $943 million in 2018.

The group now has 258 approvals and has so far filed over 350 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.

Zydus Lifesciences Share Price

929.05 6.60 (0.72%)
12-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1794.30
Dr. Reddys Lab 1279.65
Cipla 1517.20
Zydus Lifesciences 929.05
Lupin 2114.10
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×